Biolife Solutions INC Form 4 insider transactions

Biolife Solutions' Executive Vice President and Chief Scientific Officer, Aby J. Mathew, sold 404 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 343 shares of common stock at $27.02 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

BioLife Solutions CEO, Roderick de Greef, sold 46,896 shares of common stock at $23.43 per share under a pre-arranged 10b5-1 trading plan.

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 328 shares of common stock on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 987 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold a total of 20,800 shares of common stock on December 16 and 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 581 shares of common stock at $27.2 per share on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, sold 523 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 349 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 216 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 252 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Executive Vice President and Chief Scientific Officer of BioLife Solutions, Aby J. Mathew, executed multiple sales of company stock under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Marketing Officer, Todd Berard, sold 91 shares of common stock at $26.34 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 66 shares of common stock at $26.34 per share under a pre-arranged 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, sold 123 shares of common stock at $26.34 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 147 shares of common stock at $26.19 per share under a pre-arranged 10b5-1 trading plan.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 203 shares of common stock on October 30, 2024, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 311 shares of common stock on October 30, 2024, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 277 shares of common stock on October 30, 2024, to cover tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 547 shares of common stock on October 30, 2024, to satisfy tax withholding obligations.

Troy Wichterman, CFO of BioLife Solutions, sold 894 shares of common stock on October 30, 2024, at a price of $23.15 per share to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, exercised stock options and sold shares of common stock on October 15 and 16, 2024, according to a Form 4 filing with the SEC.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, exercised stock options and sold 20,000 shares of common stock on September 18 and 19, 2024, according to a Form 4 filing with the SEC.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, reports the sale of common stock under pre-arranged Rule 10b5-1 trading plans.

BioLife Solutions' Chief Marketing Officer, Todd Berard, executed multiple sales of common stock under pre-arranged 10b5-1 trading plans.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold common stock in multiple transactions under pre-arranged 10b5-1 trading plans.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, Inc., reported the sale of common stock between July and September 2024 under pre-arranged 10b5-1 trading plans.

Troy Wichterman, CFO of BioLife Solutions, sold shares of common stock in multiple transactions between July and September 2024 under pre-arranged 10b5-1 trading plans.

Garrie Richardson, Chief Revenue Officer of BioLife Solutions, sold 3,070 shares of common stock on September 16, 2024, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 3,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.